12 July Dynacure, French biotechnology company, developing drugs for the treatment of neuromuscular diseases in the ½ phase of research, announced the terms of the upcoming IPO.
Company headquartered in Ilkirsch-Graffenstaden, France, plans to attract 100 million dollars, releasing 6,3 million ADS at a cost of 15 to 17 Dollars. Taking into account the average price of the stated range, the total diluted market value of Dynacure is 339 million dollars.
Dynacure specializes in the development of drugs for the treatment of neuromuscular diseases, starting with myotubular and centronuclear myopathies (CNM). Leading candidate drug of the company, DYN101, is an antisense oligonucleotide, developed as a drug, disease modifying, for the treatment of most cases of CNM with multiple mutations as in adults, and children. The company is conducting ½ phase testing of DYN101 in Europe and in 2 Half 2021 plans to expand research to sites in the United States. In 2 Half 2022 the company plans to provide interim data on pharmacokinetics and safety, and the final results are expected in 2023 year.
Dynacure was founded in 2016 year and plans to list on the stock exchange Nasdaq under the ticker DYCU. The joint organizers of the issue of shares were J.P. Morgan, BofA Securities и Wells Fargo Securities. The company plans to hold an IPO this week, which started 12 July 2021 of the year.
